Current practices and future outlook on the integration of biomarkers in the drug development process.

Stephanie Fraser, Sarah Osgood

Bioanalysis 2017 Nov

filter terms:

Over the last decade, there has been broad incorporation of translational biomarkers into the early drug development process to predict safety concerns, measure target engagement and monitor disease progression. One goal of translational biomarkers is to create a cycle whereby preclinical readouts influence candidate selection and subsequent clinical data are fed back into research to facilitate better decision making. Successes have been limited and not as broad in scope as desired. Collaborations between industry and regulators have increased the number of qualified biomarkers; but the process is lengthy and expensive. A high level overview of translational biomarkers as well as a discussion of some of the successes and failures encountered in development is discussed here.

Citation

Stephanie Fraser, Sarah Osgood. Current practices and future outlook on the integration of biomarkers in the drug development process. Bioanalysis. 2017 Nov;9(22):1827-1837